24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients.

Drugs · 2020 · PMC7007425 · PMID 31884564

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Analysis of all available data showed a trend toward numerically larger mean IOP reductions in rescued eyes when compared with results of the censored data analysis (Fig. 2 a, b).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.